Veterinary Active Pharmaceutical Ingredients Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service Type (In House, Contract Outsourcing), By Synthesis Type (Chemical-based API, Biological API, HPAPI), By Animal Type (Production Animals, Companion Animals), By Therapeutic Category (Antiparasitic, Anti-infectives, NSAIDs, Others), By Region and Competition, 2019-2029F
Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market was valued at USD 8.39 Billion in 2023 and is anticipated t%li%project impressive growth in the forecast period with a CAGR of 7.12% through 2029. The Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing market is a crucial segment within the broader pharmaceutical industry, dedicated t%li%producing essential compounds for veterinary medications. With a focus on animal health and welfare, this market plays a vital role in ensuring the effective treatment and prevention of diseases in various animal species, including livestock, pets, and companion animals. The demand for veterinary APIs is driven by factors such as the increasing prevalence of animal diseases, rising pet ownership rates, and growing concerns regarding food safety and quality. As a result, pharmaceutical companies, contract manufacturers, and research institutions are continuously innovating and investing in the development and production of high-quality veterinary APIs. Geographically, the market exhibits a global presence, with key players operating in regions such as North America, Europe, Asia Pacific, and Latin America. Technological advancements, regulatory frameworks, and economic factors significantly influence market dynamics, shaping production processes, supply chains, and pricing strategies. Moreover, collaborations, mergers, and acquisitions are common strategies adopted by companies t%li%strengthen their market position and expand their product portfolios. Sustainability and environmental concerns are als%li%gaining traction, prompting manufacturers t%li%explore eco-friendly production methods and invest in green initiatives.
Key Market Drivers
Increasing Pet Ownership Rates
Increasing pet ownership rates worldwide are significantly boosting the Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market. As more households welcome pets int%li%their families, the demand for veterinary medications rises correspondingly. Pets, including dogs, cats, birds, and small mammals, are increasingly regarded as integral members of the family, prompting pet owners t%li%invest in their health and well-being. This cultural shift towards viewing pets as companions rather than mere animals has led t%li%a surge in spending on pet care products and services, including veterinary medicines.
The rise in pet ownership rates is driven by various factors, including urbanization, changing lifestyles, and an increasing awareness of the positive impact of pets on mental and emotional well-being. In urban areas, where space constraints and busy lifestyles often discourage traditional pet ownership, there is a growing trend towards owning smaller pets such as cats, birds, and small mammals that require less space and are more adaptable t%li%apartment living. Additionally, the COVID-19 pandemic has accelerated the trend of pet ownership, with many individuals seeking companionship and emotional support during periods of social isolation and uncertainty.
As the number of pets worldwide continues t%li%grow, s%li%does the demand for veterinary medications t%li%treat and prevent diseases. Veterinary APIs form the backbone of these medications, serving as the active ingredients that deliver therapeutic effects. Pharmaceutical companies are thus ramping up production of veterinary APIs t%li%meet this escalating demand. They are investing in research and development t%li%develop new and improved formulations that address a wide range of health concerns in pets, from common ailments like fleas and ticks t%li%more serious conditions such as diabetes and cancer.
The increasing focus on preventive healthcare for pets is driving demand for veterinary APIs used in the production of vaccines, flea and tick preventatives, and other preventive medications. Pet owners are increasingly proactive about keeping their pets healthy and preventing diseases before they occur, leading t%li%a growing market for preventive veterinary medicines. In response, pharmaceutical companies are developing innovative vaccines and preventive treatments that target a broad spectrum of diseases, further fueling growth in the veterinary API manufacturing market.
Rising Prevalence of Animal Diseases
The rising prevalence of animal diseases is a significant driver behind the burgeoning Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market. Across the globe, there has been an alarming increase in the incidence of infectious and non-infectious diseases affecting various animal species, including livestock, companion animals, and wildlife. This trend poses significant challenges t%li%animal health, welfare, and food security, prompting a surge in demand for veterinary medications and vaccines.
In the agriculture and livestock sectors, diseases such as foot-and-mouth disease, avian influenza, African swine fever, and bovine respiratory disease can have devastating effects on animal populations and agricultural economies. These diseases not only cause suffering and mortality in affected animals but als%li%result in significant economic losses due t%li%reduced productivity, trade restrictions, and control measures. As a result, there is a growing urgency t%li%develop effective preventive and therapeutic solutions t%li%combat these diseases, driving demand for veterinary APIs used in their formulation.
The increasing globalization of trade and travel has facilitated the spread of infectious diseases among animal populations, making disease control and prevention efforts more challenging. Emerging zoonotic diseases, which can be transmitted from animals t%li%humans, further underscore the importance of addressing animal health issues. Governments, regulatory agencies, and international organizations are thus prioritizing efforts t%li%strengthen disease surveillance, outbreak response, and biosecurity measures t%li%mitigate the spread of animal diseases. In response t%li%these challenges, pharmaceutical companies are ramping up production of veterinary APIs used in the production of vaccines, antimicrobial agents, parasiticides, and other veterinary medicines. These APIs serve as the active ingredients that deliver therapeutic effects, helping t%li%prevent, control, and treat a wide range of animal diseases. Additionally, there is a growing demand for diagnostic tests, biosecurity products, and veterinary healthcare services aimed at detecting and managing disease outbreaks in animals.
The rising prevalence of animal diseases is driving innovation in the veterinary pharmaceutical industry, leading t%li%the development of new and improved therapies for animal health. Pharmaceutical companies are investing in research and development t%li%develop novel drug formulations, vaccine technologies, and diagnostic tools t%li%address emerging disease threats and meet the evolving needs of the market.
Key Market Challenges
Cost Constraints
Cost constraints are a major challenge for manufacturers in the Global Veterinary API Manufacturing Market. Developing and manufacturing veterinary APIs involves significant investments in research and development, raw materials, manufacturing processes, and quality assurance. Additionally, the market for veterinary medicines is relatively smaller compared t%li%the human pharmaceutical market, limiting economies of scale and increasing production costs. Moreover, pricing pressures from competition, generic alternatives, and government reimbursement policies can further squeeze profit margins for manufacturers. Balancing the need for affordable veterinary medicines with the costs of production presents a significant challenge for industry players.
Supply Chain Disruptions
Supply chain disruptions pose a significant challenge t%li%the Global Veterinary API Manufacturing Market. The industry relies on a complex network of suppliers, contract manufacturers, distributors, and logistics providers t%li%source raw materials, manufacture APIs, and deliver finished products t%li%customers. Disruptions in the supply chain, such as natural disasters, geopolitical tensions, transportation bottlenecks, or raw material shortages, can disrupt production schedules, lead t%li%inventory shortages, and impact product availability. Additionally, the COVID-19 pandemic highlighted vulnerabilities in global supply chains, further exacerbating challenges related t%li%sourcing, production, and distribution of veterinary APIs.
Key Market Trends
Expansion of Companion Animal Pharmaceutical Market
The global veterinary active pharmaceutical ingredients (API) manufacturing market is experiencing significant growth, propelled by the expanding companion animal pharmaceutical market. Companion animals, including dogs, cats, and horses, have become integral parts of households worldwide, leading t%li%a surge in demand for specialized veterinary medicines tailored t%li%their unique healthcare needs. As pet ownership continues t%li%rise globally, s%li%does the expenditure on companion animal healthcare. Pet owners are increasingly investing in preventive healthcare measures, diagnostics, and advanced treatment options t%li%ensure the health and well-being of their beloved pets. This growing emphasis on pet healthcare has spurred the development and commercialization of a wide range of veterinary pharmaceuticals, driving the demand for high-quality active pharmaceutical ingredients.
One of the key factors driving the expansion of the companion animal pharmaceutical market is the humanization of pets. Pet owners increasingly view their animals as family members and are willing t%li%spend more on their healthcare needs. This shift in perception has led t%li%the development of specialized veterinary medicines targeting conditions such as arthritis, cancer, diabetes, and behavioral disorders in companion animals. Consequently, pharmaceutical companies are investing heavily in research and development t%li%create innovative veterinary APIs tailored t%li%address these specific therapeutic areas.
Advancements in veterinary medicine, including novel drug delivery systems and biopharmaceuticals, are driving the growth of the companion animal pharmaceutical market. Biotechnology-derived drugs, such as monoclonal antibodies and recombinant proteins, offer promising treatment options for various diseases in companion animals, further fueling market expansion.
The globalization of the companion animal pharmaceutical industry is als%li%contributing t%li%the growth of the veterinary API manufacturing market. Pharmaceutical companies are expanding their presence in emerging markets t%li%capitalize on the growing demand for veterinary medicines. Moreover, strategic collaborations, partnerships, and acquisitions are reshaping the competitive landscape of the industry, driving innovation and market growth.
Emergence of Biopharmaceuticals for Veterinary Use
The emergence of biopharmaceuticals for veterinary use is reshaping the landscape of the global veterinary active pharmaceutical ingredients (API) manufacturing market. Biopharmaceuticals, derived from biological sources such as living cells or organisms, offer novel treatment options for various diseases in animals, driving significant growth in the veterinary pharmaceutical sector. Biopharmaceuticals for veterinary use encompass a wide range of products, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies. These innovative therapies provide targeted and efficacious treatments for conditions ranging from infectious diseases t%li%chronic illnesses in companion animals and livestock.
Primary drivers behind the adoption of biopharmaceuticals in veterinary medicine is their ability t%li%address unmet medical needs and offer superior therapeutic outcomes compared t%li%traditional pharmaceuticals. Monoclonal antibodies, for example, can specifically target disease-causing agents with high precision, minimizing adverse effects and improving treatment efficacy. Similarly, recombinant proteins offer targeted therapeutic interventions for conditions such as hormone deficiencies and immune disorders in animals.
The development of biopharmaceuticals for veterinary use is supported by advancements in biotechnology and genetic engineering. Cutting-edge technologies enable the production of complex biological molecules in large quantities, making biopharmaceuticals more accessible and cost-effective for veterinary applications. Additionally, ongoing research in areas such as gene editing and regenerative medicine holds promise for the development of innovative biopharmaceutical therapies for veterinary use.
The globalization of the veterinary pharmaceutical industry is als%li%driving the growth of the veterinary API manufacturing market for biopharmaceuticals. Pharmaceutical companies are expanding their portfolios t%li%include biotechnology-derived veterinary medicines, leveraging their expertise in bioprocessing and regulatory compliance t%li%meet the growing demand for advanced veterinary therapies worldwide.
Segmental Insights
Synthesis Type Insights
In the Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market, the chemical-based API segment has emerged as the dominant player based on synthesis type. Chemical-based APIs have a long-established presence in the pharmaceutical industry, offering a wide range of compounds that are essential for the formulation of veterinary medicines. Their extensive use and proven efficacy make them a preferred choice for pharmaceutical manufacturers. Chemical synthesis allows for the production of APIs in large quantities at relatively low costs, making them commercially viable for mass production. This scalability is crucial in meeting the growing demand for veterinary medicines worldwide.
Futhermore, biological API segment is anticipated t%li%grow at the fastest rate in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market. advancements in biotechnology have paved the way for the development of novel biological APIs tailored for veterinary use. Biopharmaceuticals derived from living organisms offer targeted and efficacious treatment options for a wide range of animal diseases, driving demand for biological APIs.
Regional Insights
In 2023, North America asserted its dominance in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, largely due t%li%a convergence of several key factors. Firstly, the region boasts a robust infrastructure for pharmaceutical manufacturing, with advanced research and development capabilities and stringent regulatory standards that ensure high-quality production. This creates an environment conducive t%li%innovation and product development, allowing North American companies t%li%stay at the forefront of the veterinary API market.
North America is home t%li%a significant concentration of leading pharmaceutical companies specializing in veterinary medicines. These companies leverage their extensive resources, expertise, and networks t%li%drive growth and maintain a competitive edge in the global market. The region benefits from a strong veterinary healthcare system and a growing pet population, particularly in the United States and Canada. This increases the demand for veterinary pharmaceuticals, including active pharmaceutical ingredients, driving the growth of the market in North America.
Key Market Players
In this report, the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market.
Available Customizations:
Global Veterinary Active Pharmaceutical Ingredients Manufacturing market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
Increasing Pet Ownership Rates
Increasing pet ownership rates worldwide are significantly boosting the Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market. As more households welcome pets int%li%their families, the demand for veterinary medications rises correspondingly. Pets, including dogs, cats, birds, and small mammals, are increasingly regarded as integral members of the family, prompting pet owners t%li%invest in their health and well-being. This cultural shift towards viewing pets as companions rather than mere animals has led t%li%a surge in spending on pet care products and services, including veterinary medicines.
The rise in pet ownership rates is driven by various factors, including urbanization, changing lifestyles, and an increasing awareness of the positive impact of pets on mental and emotional well-being. In urban areas, where space constraints and busy lifestyles often discourage traditional pet ownership, there is a growing trend towards owning smaller pets such as cats, birds, and small mammals that require less space and are more adaptable t%li%apartment living. Additionally, the COVID-19 pandemic has accelerated the trend of pet ownership, with many individuals seeking companionship and emotional support during periods of social isolation and uncertainty.
As the number of pets worldwide continues t%li%grow, s%li%does the demand for veterinary medications t%li%treat and prevent diseases. Veterinary APIs form the backbone of these medications, serving as the active ingredients that deliver therapeutic effects. Pharmaceutical companies are thus ramping up production of veterinary APIs t%li%meet this escalating demand. They are investing in research and development t%li%develop new and improved formulations that address a wide range of health concerns in pets, from common ailments like fleas and ticks t%li%more serious conditions such as diabetes and cancer.
The increasing focus on preventive healthcare for pets is driving demand for veterinary APIs used in the production of vaccines, flea and tick preventatives, and other preventive medications. Pet owners are increasingly proactive about keeping their pets healthy and preventing diseases before they occur, leading t%li%a growing market for preventive veterinary medicines. In response, pharmaceutical companies are developing innovative vaccines and preventive treatments that target a broad spectrum of diseases, further fueling growth in the veterinary API manufacturing market.
Rising Prevalence of Animal Diseases
The rising prevalence of animal diseases is a significant driver behind the burgeoning Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market. Across the globe, there has been an alarming increase in the incidence of infectious and non-infectious diseases affecting various animal species, including livestock, companion animals, and wildlife. This trend poses significant challenges t%li%animal health, welfare, and food security, prompting a surge in demand for veterinary medications and vaccines.
In the agriculture and livestock sectors, diseases such as foot-and-mouth disease, avian influenza, African swine fever, and bovine respiratory disease can have devastating effects on animal populations and agricultural economies. These diseases not only cause suffering and mortality in affected animals but als%li%result in significant economic losses due t%li%reduced productivity, trade restrictions, and control measures. As a result, there is a growing urgency t%li%develop effective preventive and therapeutic solutions t%li%combat these diseases, driving demand for veterinary APIs used in their formulation.
The increasing globalization of trade and travel has facilitated the spread of infectious diseases among animal populations, making disease control and prevention efforts more challenging. Emerging zoonotic diseases, which can be transmitted from animals t%li%humans, further underscore the importance of addressing animal health issues. Governments, regulatory agencies, and international organizations are thus prioritizing efforts t%li%strengthen disease surveillance, outbreak response, and biosecurity measures t%li%mitigate the spread of animal diseases. In response t%li%these challenges, pharmaceutical companies are ramping up production of veterinary APIs used in the production of vaccines, antimicrobial agents, parasiticides, and other veterinary medicines. These APIs serve as the active ingredients that deliver therapeutic effects, helping t%li%prevent, control, and treat a wide range of animal diseases. Additionally, there is a growing demand for diagnostic tests, biosecurity products, and veterinary healthcare services aimed at detecting and managing disease outbreaks in animals.
The rising prevalence of animal diseases is driving innovation in the veterinary pharmaceutical industry, leading t%li%the development of new and improved therapies for animal health. Pharmaceutical companies are investing in research and development t%li%develop novel drug formulations, vaccine technologies, and diagnostic tools t%li%address emerging disease threats and meet the evolving needs of the market.
Key Market Challenges
Cost Constraints
Cost constraints are a major challenge for manufacturers in the Global Veterinary API Manufacturing Market. Developing and manufacturing veterinary APIs involves significant investments in research and development, raw materials, manufacturing processes, and quality assurance. Additionally, the market for veterinary medicines is relatively smaller compared t%li%the human pharmaceutical market, limiting economies of scale and increasing production costs. Moreover, pricing pressures from competition, generic alternatives, and government reimbursement policies can further squeeze profit margins for manufacturers. Balancing the need for affordable veterinary medicines with the costs of production presents a significant challenge for industry players.
Supply Chain Disruptions
Supply chain disruptions pose a significant challenge t%li%the Global Veterinary API Manufacturing Market. The industry relies on a complex network of suppliers, contract manufacturers, distributors, and logistics providers t%li%source raw materials, manufacture APIs, and deliver finished products t%li%customers. Disruptions in the supply chain, such as natural disasters, geopolitical tensions, transportation bottlenecks, or raw material shortages, can disrupt production schedules, lead t%li%inventory shortages, and impact product availability. Additionally, the COVID-19 pandemic highlighted vulnerabilities in global supply chains, further exacerbating challenges related t%li%sourcing, production, and distribution of veterinary APIs.
Key Market Trends
Expansion of Companion Animal Pharmaceutical Market
The global veterinary active pharmaceutical ingredients (API) manufacturing market is experiencing significant growth, propelled by the expanding companion animal pharmaceutical market. Companion animals, including dogs, cats, and horses, have become integral parts of households worldwide, leading t%li%a surge in demand for specialized veterinary medicines tailored t%li%their unique healthcare needs. As pet ownership continues t%li%rise globally, s%li%does the expenditure on companion animal healthcare. Pet owners are increasingly investing in preventive healthcare measures, diagnostics, and advanced treatment options t%li%ensure the health and well-being of their beloved pets. This growing emphasis on pet healthcare has spurred the development and commercialization of a wide range of veterinary pharmaceuticals, driving the demand for high-quality active pharmaceutical ingredients.
One of the key factors driving the expansion of the companion animal pharmaceutical market is the humanization of pets. Pet owners increasingly view their animals as family members and are willing t%li%spend more on their healthcare needs. This shift in perception has led t%li%the development of specialized veterinary medicines targeting conditions such as arthritis, cancer, diabetes, and behavioral disorders in companion animals. Consequently, pharmaceutical companies are investing heavily in research and development t%li%create innovative veterinary APIs tailored t%li%address these specific therapeutic areas.
Advancements in veterinary medicine, including novel drug delivery systems and biopharmaceuticals, are driving the growth of the companion animal pharmaceutical market. Biotechnology-derived drugs, such as monoclonal antibodies and recombinant proteins, offer promising treatment options for various diseases in companion animals, further fueling market expansion.
The globalization of the companion animal pharmaceutical industry is als%li%contributing t%li%the growth of the veterinary API manufacturing market. Pharmaceutical companies are expanding their presence in emerging markets t%li%capitalize on the growing demand for veterinary medicines. Moreover, strategic collaborations, partnerships, and acquisitions are reshaping the competitive landscape of the industry, driving innovation and market growth.
Emergence of Biopharmaceuticals for Veterinary Use
The emergence of biopharmaceuticals for veterinary use is reshaping the landscape of the global veterinary active pharmaceutical ingredients (API) manufacturing market. Biopharmaceuticals, derived from biological sources such as living cells or organisms, offer novel treatment options for various diseases in animals, driving significant growth in the veterinary pharmaceutical sector. Biopharmaceuticals for veterinary use encompass a wide range of products, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies. These innovative therapies provide targeted and efficacious treatments for conditions ranging from infectious diseases t%li%chronic illnesses in companion animals and livestock.
Primary drivers behind the adoption of biopharmaceuticals in veterinary medicine is their ability t%li%address unmet medical needs and offer superior therapeutic outcomes compared t%li%traditional pharmaceuticals. Monoclonal antibodies, for example, can specifically target disease-causing agents with high precision, minimizing adverse effects and improving treatment efficacy. Similarly, recombinant proteins offer targeted therapeutic interventions for conditions such as hormone deficiencies and immune disorders in animals.
The development of biopharmaceuticals for veterinary use is supported by advancements in biotechnology and genetic engineering. Cutting-edge technologies enable the production of complex biological molecules in large quantities, making biopharmaceuticals more accessible and cost-effective for veterinary applications. Additionally, ongoing research in areas such as gene editing and regenerative medicine holds promise for the development of innovative biopharmaceutical therapies for veterinary use.
The globalization of the veterinary pharmaceutical industry is als%li%driving the growth of the veterinary API manufacturing market for biopharmaceuticals. Pharmaceutical companies are expanding their portfolios t%li%include biotechnology-derived veterinary medicines, leveraging their expertise in bioprocessing and regulatory compliance t%li%meet the growing demand for advanced veterinary therapies worldwide.
Segmental Insights
Synthesis Type Insights
In the Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market, the chemical-based API segment has emerged as the dominant player based on synthesis type. Chemical-based APIs have a long-established presence in the pharmaceutical industry, offering a wide range of compounds that are essential for the formulation of veterinary medicines. Their extensive use and proven efficacy make them a preferred choice for pharmaceutical manufacturers. Chemical synthesis allows for the production of APIs in large quantities at relatively low costs, making them commercially viable for mass production. This scalability is crucial in meeting the growing demand for veterinary medicines worldwide.
Futhermore, biological API segment is anticipated t%li%grow at the fastest rate in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market. advancements in biotechnology have paved the way for the development of novel biological APIs tailored for veterinary use. Biopharmaceuticals derived from living organisms offer targeted and efficacious treatment options for a wide range of animal diseases, driving demand for biological APIs.
Regional Insights
In 2023, North America asserted its dominance in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, largely due t%li%a convergence of several key factors. Firstly, the region boasts a robust infrastructure for pharmaceutical manufacturing, with advanced research and development capabilities and stringent regulatory standards that ensure high-quality production. This creates an environment conducive t%li%innovation and product development, allowing North American companies t%li%stay at the forefront of the veterinary API market.
North America is home t%li%a significant concentration of leading pharmaceutical companies specializing in veterinary medicines. These companies leverage their extensive resources, expertise, and networks t%li%drive growth and maintain a competitive edge in the global market. The region benefits from a strong veterinary healthcare system and a growing pet population, particularly in the United States and Canada. This increases the demand for veterinary pharmaceuticals, including active pharmaceutical ingredients, driving the growth of the market in North America.
Key Market Players
- Zoetis Inc.
- Alivira Animal Health Limited
- Ofichem Group
- Chempr%li%Group
- Siflon Group
- Qilu Animal Health Products Co., Ltd.
- Chem%li%Holding, S.L
- SUAN FARMA S.A.U
- MENADIONA
- Excel Industries Ltd
In this report, the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service Type:
- In House
- Contract Outsourcing
- Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Type:
- Chemical-based API
- Biological API
- HPAPI
- Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Animal Type:
- Production Animals
- Companion Animals
- Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Therapeutic Category:
- Antiparasitic
- Anti-infectives
- NSAIDs
- Others
- Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market.
Available Customizations:
Global Veterinary Active Pharmaceutical Ingredients Manufacturing market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. GLOBAL VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Service Type (In House, Contract Outsourcing)
5.2.2. By Synthesis Type (Chemical-based API, Biological API, HPAPI)
5.2.3. By Animal Type (Production Animals, Companion Animals)
5.2.4. By Therapeutic Category (Antiparasitic, Anti-infectives, NSAIDs, Others)
5.2.5. By Company (2023)
5.2.6. By Region
5.3. Market Map
6. NORTH AMERICA VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Service Type
6.2.2. By Synthesis Type
6.2.3. By Animal Type
6.2.4. By Therapeutic Category
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Service Type
6.3.1.2.2. By Synthesis Type
6.3.1.2.3. By Animal Type
6.3.1.2.4. By Therapeutic Category
6.3.2. Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Service Type
6.3.2.2.2. By Synthesis Type
6.3.2.2.3. By Animal Type
6.3.2.2.4. By Therapeutic Category
6.3.3. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Service Type
6.3.3.2.2. By Synthesis Type
6.3.3.2.3. By Animal Type
6.3.3.2.4. By Therapeutic Category
7. EUROPE VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Service Type
7.2.2. By Synthesis Type
7.2.3. By Animal Type
7.2.4. By Therapeutic Category
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Service Type
7.3.1.2.2. By Synthesis Type
7.3.1.2.3. By Animal Type
7.3.1.2.4. By Therapeutic Category
7.3.2. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Service Type
7.3.2.2.2. By Synthesis Type
7.3.2.2.3. By Animal Type
7.3.2.2.4. By Therapeutic Category
7.3.3. United Kingdom Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Service Type
7.3.3.2.2. By Synthesis Type
7.3.3.2.3. By Animal Type
7.3.3.2.4. By Therapeutic Category
7.3.4. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Service Type
7.3.4.2.2. By Synthesis Type
7.3.4.2.3. By Animal Type
7.3.4.2.4. By Therapeutic Category
7.3.5. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Service Type
7.3.5.2.2. By Synthesis Type
7.3.5.2.3. By Animal Type
7.3.5.2.4. By Therapeutic Category
8. ASIA-PACIFIC VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Service Type
8.2.2. By Synthesis Type
8.2.3. By Animal Type
8.2.4. By Therapeutic Category
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Service Type
8.3.1.2.2. By Synthesis Type
8.3.1.2.3. By Animal Type
8.3.1.2.4. By Therapeutic Category
8.3.2. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Service Type
8.3.2.2.2. By Synthesis Type
8.3.2.2.3. By Animal Type
8.3.2.2.4. By Therapeutic Category
8.3.3. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Service Type
8.3.3.2.2. By Synthesis Type
8.3.3.2.3. By Animal Type
8.3.3.2.4. By Therapeutic Category
8.3.4. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Service Type
8.3.4.2.2. By Synthesis Type
8.3.4.2.3. By Animal Type
8.3.4.2.4. By Therapeutic Category
8.3.5. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Service Type
8.3.5.2.2. By Synthesis Type
8.3.5.2.3. By Animal Type
8.3.5.2.4. By Therapeutic Category
9. SOUTH AMERICA VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Service Type
9.2.2. By Synthesis Type
9.2.3. By Animal Type
9.2.4. By Therapeutic Category
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Service Type
9.3.1.2.2. By Synthesis Type
9.3.1.2.3. By Animal Type
9.3.1.2.4. By Therapeutic Category
9.3.2. Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Service Type
9.3.2.2.2. By Synthesis Type
9.3.2.2.3. By Animal Type
9.3.2.2.4. By Therapeutic Category
9.3.3. Colombia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Service Type
9.3.3.2.2. By Synthesis Type
9.3.3.2.3. By Animal Type
9.3.3.2.4. By Therapeutic Category
10. MIDDLE EAST AND AFRICA VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Service Type
10.2.2. By Synthesis Type
10.2.3. By Animal Type
10.2.4. By Therapeutic Category
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Service Type
10.3.1.2.2. By Synthesis Type
10.3.1.2.3. By Animal Type
10.3.1.2.4. By Therapeutic Category
10.3.2. Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Service Type
10.3.2.2.2. By Synthesis Type
10.3.2.2.3. By Animal Type
10.3.2.2.4. By Therapeutic Category
10.3.3. UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Service Type
10.3.3.2.2. By Synthesis Type
10.3.3.2.3. By Animal Type
10.3.3.2.4. By Therapeutic Category
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. PORTERS FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. COMPETITIVE LANDSCAPE
14.1. Zoetis Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Alivira Animal Health Limited
14.3. Ofichem Group
14.4. Chempro Group
14.5. Siflon Group
14.6. Qilu Animal Health Products Co., Ltd.
14.7. Chemo Holding, S.L
14.8. SUAN FARMA S.A.U
14.9. MENADIONA
14.10. Excel Industries Ltd
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. GLOBAL VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Service Type (In House, Contract Outsourcing)
5.2.2. By Synthesis Type (Chemical-based API, Biological API, HPAPI)
5.2.3. By Animal Type (Production Animals, Companion Animals)
5.2.4. By Therapeutic Category (Antiparasitic, Anti-infectives, NSAIDs, Others)
5.2.5. By Company (2023)
5.2.6. By Region
5.3. Market Map
6. NORTH AMERICA VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Service Type
6.2.2. By Synthesis Type
6.2.3. By Animal Type
6.2.4. By Therapeutic Category
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Service Type
6.3.1.2.2. By Synthesis Type
6.3.1.2.3. By Animal Type
6.3.1.2.4. By Therapeutic Category
6.3.2. Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Service Type
6.3.2.2.2. By Synthesis Type
6.3.2.2.3. By Animal Type
6.3.2.2.4. By Therapeutic Category
6.3.3. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Service Type
6.3.3.2.2. By Synthesis Type
6.3.3.2.3. By Animal Type
6.3.3.2.4. By Therapeutic Category
7. EUROPE VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Service Type
7.2.2. By Synthesis Type
7.2.3. By Animal Type
7.2.4. By Therapeutic Category
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Service Type
7.3.1.2.2. By Synthesis Type
7.3.1.2.3. By Animal Type
7.3.1.2.4. By Therapeutic Category
7.3.2. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Service Type
7.3.2.2.2. By Synthesis Type
7.3.2.2.3. By Animal Type
7.3.2.2.4. By Therapeutic Category
7.3.3. United Kingdom Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Service Type
7.3.3.2.2. By Synthesis Type
7.3.3.2.3. By Animal Type
7.3.3.2.4. By Therapeutic Category
7.3.4. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Service Type
7.3.4.2.2. By Synthesis Type
7.3.4.2.3. By Animal Type
7.3.4.2.4. By Therapeutic Category
7.3.5. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Service Type
7.3.5.2.2. By Synthesis Type
7.3.5.2.3. By Animal Type
7.3.5.2.4. By Therapeutic Category
8. ASIA-PACIFIC VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Service Type
8.2.2. By Synthesis Type
8.2.3. By Animal Type
8.2.4. By Therapeutic Category
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Service Type
8.3.1.2.2. By Synthesis Type
8.3.1.2.3. By Animal Type
8.3.1.2.4. By Therapeutic Category
8.3.2. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Service Type
8.3.2.2.2. By Synthesis Type
8.3.2.2.3. By Animal Type
8.3.2.2.4. By Therapeutic Category
8.3.3. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Service Type
8.3.3.2.2. By Synthesis Type
8.3.3.2.3. By Animal Type
8.3.3.2.4. By Therapeutic Category
8.3.4. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Service Type
8.3.4.2.2. By Synthesis Type
8.3.4.2.3. By Animal Type
8.3.4.2.4. By Therapeutic Category
8.3.5. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Service Type
8.3.5.2.2. By Synthesis Type
8.3.5.2.3. By Animal Type
8.3.5.2.4. By Therapeutic Category
9. SOUTH AMERICA VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Service Type
9.2.2. By Synthesis Type
9.2.3. By Animal Type
9.2.4. By Therapeutic Category
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Service Type
9.3.1.2.2. By Synthesis Type
9.3.1.2.3. By Animal Type
9.3.1.2.4. By Therapeutic Category
9.3.2. Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Service Type
9.3.2.2.2. By Synthesis Type
9.3.2.2.3. By Animal Type
9.3.2.2.4. By Therapeutic Category
9.3.3. Colombia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Service Type
9.3.3.2.2. By Synthesis Type
9.3.3.2.3. By Animal Type
9.3.3.2.4. By Therapeutic Category
10. MIDDLE EAST AND AFRICA VETERINARY ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Service Type
10.2.2. By Synthesis Type
10.2.3. By Animal Type
10.2.4. By Therapeutic Category
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Service Type
10.3.1.2.2. By Synthesis Type
10.3.1.2.3. By Animal Type
10.3.1.2.4. By Therapeutic Category
10.3.2. Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Service Type
10.3.2.2.2. By Synthesis Type
10.3.2.2.3. By Animal Type
10.3.2.2.4. By Therapeutic Category
10.3.3. UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Service Type
10.3.3.2.2. By Synthesis Type
10.3.3.2.3. By Animal Type
10.3.3.2.4. By Therapeutic Category
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. PORTERS FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. COMPETITIVE LANDSCAPE
14.1. Zoetis Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Alivira Animal Health Limited
14.3. Ofichem Group
14.4. Chempro Group
14.5. Siflon Group
14.6. Qilu Animal Health Products Co., Ltd.
14.7. Chemo Holding, S.L
14.8. SUAN FARMA S.A.U
14.9. MENADIONA
14.10. Excel Industries Ltd
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
